A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin

Lilly

Status and phase: Not yet enrolling; Phase 2

Conditions: Diabetes Mellitus, Type 2

Treatments: Drug: Degludec; Drug: LY3938577

Study type: Interventional

Funder types: Industry

Identifiers

NCT07215312

27409

J4P-MC-IYAC (Other Identifier)

Details and patient eligibility

About

The purpose of this study is to see how well LY3938577 works and how safe it is compared to degludec in people with type 2 diabetes. Participation in the study will last about 26 weeks.

Enrollment: 100 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Have type 2 diabetes
• Are receiving ≥20 units of basal insulin per day and ≤55 units/day and ≤1.5 units/kg/day at screening
• Have hemoglobin A1c (HbA1c) 7.5% to 10.5% inclusive
• Have a body mass index (BMI) of 20 or higher and less than 35 kilograms per square meter (kg/m2)

Exclusion criteria

• Have type 1 diabetes

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

100 participants in 2 patient groups

LY3938577

Experimental group

Description:

Participants will receive LY3938577 subcutaneously (SC)

Treatment:

Drug: LY3938577

Degludec

Active Comparator group

Description:

Participants will receive degludec SC

Treatment:

Drug: Degludec